Alzinova AB (publ) announced that the first patient has been dosed with a higher dose in the company's phase 1b study (part A2) with the vaccine candidate ALZ-101. The treatment is given to six patients who are treated with 400 µg ALZ-101 over a 16-week period. The full analysis from the first part of the phase 1b study (part A), reported in early 2024, confirmed the favourable safety and tolerability profile of the ALZ-101 vaccine candidate.

In addition, a high frequency of immune response was demonstrated, showing that patients treated with ALZ-101 responded with antibody levels that increased with the number of doses given. The analysis also showed that patients dosed with the highest dose of the vaccine had a higher response rate. Based on the favourable results, Alzinova applied for an extension of the study (part A2) to evaluate an additional higher dose.

This strengthens Alzinova's knowledge of, among other things, dosing of ALZ-101, which optimises the conditions for a future clinical phase 2 study. The first patient in part A2 has now been dosed with 400 µg of the vaccine candidate ALZ-101. The high-dose part is done as an open-label part of the study and includes a total of six patients who will be treated on four occasions over a 16-week period.

The patients will then be followed up for another four weeks.